Eculizumab for atypical hemolytic-uremic syndrome in India: First report from India and the challenges faced

Much progress has been made in understanding the pathophysiology and treatment of atypical hemolytic uremic syndrome (aHUS). Plasma therapy is the mainstay of treatment for aHUS. The availability of the first effective anti-complement therapeutic agent, eculizumab, has dramatically changed the outlo...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Indian J Nephrol
Egile Nagusiak: Sethi, S. K., Rohatgi, S., Dragon-Durey, M. A., Raghunathan, V., Dhaliwal, M., Rawat, A., Jha, P., Bansal, S. B., Raina, R., Kher, V.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Medknow Publications & Media Pvt Ltd 2017
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5255992/
https://ncbi.nlm.nih.gov/pubmed/28182046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0971-4065.179369
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak